Total Payments
$4,175
2024 Payments
$526.07
Companies
44
Transactions
299
Medicare Patients
7,674
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$4,119 (98.7%)
Education$55.09 (1.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,119 | 295 | 98.7% |
| Education | $55.09 | 4 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $609.21 | 42 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $601.97 | 45 | $0 (2024) |
| Genentech USA, Inc. | $326.60 | 30 | $0 (2024) |
| Merck Sharp & Dohme LLC | $244.85 | 18 | $0 (2023) |
| PFIZER INC. | $244.31 | 18 | $0 (2024) |
| Exelixis Inc. | $241.68 | 24 | $0 (2024) |
| Eisai Inc. | $186.86 | 14 | $0 (2024) |
| Janssen Biotech, Inc. | $178.80 | 14 | $0 (2019) |
| Seattle Genetics, Inc. | $162.97 | 12 | $0 (2019) |
| Cook Medical LLC | $154.28 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $526.07 | 32 | Daiichi Sankyo Inc. ($66.93) |
| 2023 | $245.36 | 7 | Cook Medical LLC ($154.28) |
| 2022 | $26.69 | 2 | Adaptive Biotechnologies Corporation ($14.61) |
| 2021 | $67.17 | 5 | Janssen Pharmaceuticals, Inc ($30.73) |
| 2020 | $305.13 | 21 | Novartis Pharmaceuticals Corporation ($86.47) |
| 2019 | $853.46 | 68 | Novartis Pharmaceuticals Corporation ($203.07) |
| 2018 | $1,035 | 97 | E.R. Squibb & Sons, L.L.C. ($180.99) |
| 2017 | $1,116 | 67 | E.R. Squibb & Sons, L.L.C. ($290.88) |
All Payment Transactions
299 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/21/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/15/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.26 | General |
| 09/13/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: NONE | ||||||
| 09/12/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/12/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: HEMATOLOGY | ||||||
| 09/12/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Hematology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 08/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.26 | General |
| 06/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: Rare Disease | ||||||
| 06/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Rare Disease | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.51 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,630 | 4,702 | $1.8M | $337,418 |
| 2022 | 10 | 1,843 | 5,719 | $1.7M | $342,741 |
| 2021 | 10 | 2,053 | 6,230 | $1.7M | $388,354 |
| 2020 | 11 | 2,148 | 6,847 | $1.2M | $358,954 |
Total Patients
7,674
Total Services
23,498
Medicare Billing
$1.4M
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 683 | 2,595 | $1.5M | $266,765 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 185 | $104,728 | $15,300 | 14.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 68 | 68 | $65,782 | $12,505 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 81 | 160 | $63,942 | $11,257 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 58 | 74 | $58,406 | $10,375 | 17.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 474 | 1,230 | $14,760 | $10,282 | 69.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 154 | 305 | $10,980 | $2,291 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 15 | $11,924 | $2,060 | 17.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 31 | $18,349 | $1,987 | 10.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 16 | $9,103 | $1,766 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $8,780 | $1,722 | 19.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 11 | $5,193 | $1,110 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 696 | 2,733 | $1.4M | $280,994 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 153 | 387 | $142,234 | $28,654 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 54 | 54 | $51,321 | $10,004 | 19.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 37 | 42 | $29,456 | $6,668 | 22.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 642 | 1,932 | $22,382 | $5,691 | 25.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 178 | 479 | $17,244 | $3,674 | 21.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $11,013 | $2,203 | 20.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 31 | $9,484 | $1,871 | 19.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 22 | $9,812 | $1,829 | 18.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 21 | 24 | $5,432 | $1,153 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 736 | 2,824 | $1.3M | $302,870 | 22.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 235 | 641 | $212,879 | $49,581 | 23.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 50 | 50 | $44,670 | $9,579 | 21.4% |
About Dr. Seth Cohen, MD
Dr. Seth Cohen, MD is a Medical Oncology healthcare provider based in West Long Branch, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548295306.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seth Cohen, MD has received a total of $4,175 in payments from pharmaceutical and medical device companies, with $526.07 received in 2024. These payments were reported across 299 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($4,119).
As a Medicare-enrolled provider, Cohen has provided services to 7,674 Medicare beneficiaries, totaling 23,498 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location West Long Branch, NJ
- Active Since 07/11/2006
- Last Updated 04/05/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1548295306
Products in Payments
- OPDIVO (Biological) $437.08
- ADCETRIS (Biological) $191.59
- Cabometyx (Drug) $183.41
- DARZALEX (Biological) $178.80
- TASIGNA (Drug) $159.52
- RESONANCE (Device) $154.28
- KEYTRUDA (Biological) $133.92
- PROMACTA (Drug) $128.48
- XTANDI (Drug) $127.43
- Neulasta (Biological) $122.44
- TECENTRIQ (Biological) $114.86
- Halaven (Drug) $96.89
- Lenvima (Drug) $89.97
- KISQALI (Drug) $88.36
- VIBERZI (Drug) $78.94
- SUTENT (Drug) $74.68
- Perjeta (Biological) $62.31
- JADENU (Drug) $60.22
- MEKINIST (Drug) $58.94
- REBLOZYL (Biological) $58.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.